<DOC>
	<DOCNO>NCT02171650</DOCNO>
	<brief_summary>The primary objective collect safety data BIBW 2992 .</brief_summary>
	<brief_title>BIBW 2992 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Male female patient complete prescribed course 1200.1 1200.2 study without clinical disease progression Age 18 year old Life expectancy least three ( 3 ) month Written inform consent consistent International Conference Harmonization Good Clinical Practice guideline Eastern Cooperative Oncology Group ( ECOG ) performance score 0 , 1 2 Patients must recover previous surgery Active infectious disease Gastrointestinal disorder may interfere absorption study drug chronic diarrhea Serious illness concomitant nononcological disease consider investigator incompatible protocol Patients untreated symptomatic brain metastasis . Patients treat , asymptomatic brain metastasis eligible change brain disease status least eight ( 8 ) week , history cerebral edema bleed past eight ( 8 ) week requirement steroid antiepileptic therapy Cardiac leave ventricular function rest ejection fraction &gt; = CTC Grade 1 Absolute neutrophil count ( ANC ) less 1500 / mm3 Platelet count less 100 000 / mm3 Bilirubin great 1.5 mg / dl ( &gt; 26 μmol / L , Systeme International ( SI ) unit equivalent ) Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great three time upper limit normal ( related liver metastasis great five time upper limit normal ) Serum creatinine great 1.5 mg / dl ( &gt; 132 μmol / L , SI unit equivalent ) Women men sexually active unwilling use medically acceptable method birth control Pregnancy breastfeed Treatment investigational drug ; chemotherapy , immunotherapy , radiotherapy hormone therapy ( exclude Luteinizing hormonereleasing hormone agonist , hormone take breast cancer , bisphosphonates ) , participation clinical study 1200.1 1200.2 Patients unable comply protocol Active alcohol drug abuse Patients recover doselimiting toxicity The patient eligible retreatment previous course finish . Patients eligible following condition meet : Patients clinical sign disease progression late Xray , CT , MRI US reveal progressive disease Cardiac leave ventricular function CTC Grade ≥ 2 time previous course Patients fulfil Exclusion Criteria list Section 3.3 Day 29 previous course Patient recover doselimiting toxicity ( DLT ) 14 day last administration BIBW2992 previous course . Recovery define return baseline condition ( Visit 1 1200.1 Visit 1 1200.2 ) CTC Grade 1 , whichever high .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>